The study of diabetes medications revealed that dipeptidy-l peptidase 4 inhibitors were the most prescribed drugs (214 patients, 66.3%), followed by biguanides (168 patients, 52.0%), and insulin (71 patients, 22.0%) (Table II). This evidence concerns the gene INS and diabetes mellitus.